Archive | Artificial Intelligence (AI) RSS feed for this section

Winners of Digital RESI June 2021 Innovator’s Pitch Challenge (IPC)

17 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Digital Redefining Early Stage Investments (RESI) June ended on a high note last week, again providing a valuable platform for early-stage life science companies and investors/strategic partners to connect and start dialogue.

This RESI also featured the largest number of Innovator’s Pitch Challenge companies, with almost fifty companies participating. Each company was assigned to one of ten live Q&A sessions featuring investors and industry partners, based on sector/technology.

Attendees voted for their favorite companies throughout the three days of the conference. Check out the winners below!

1st Place – Throne Biotechnologies

Throne is an American therapeutics company aimed at commercializing a novel stem cell technology that can fundamentally reverse diabetes, alopecia areata and other autoimmune diseases through immune education. The patented technology is recognized as the leading “practical cure project” for type 1 diabetes among 594 global projects (JDCA 2020). Stem Cell Educator therapy is a single dialysis-like treatment that fundamentally “resets” a patient’s immune system and corrects the underlying autoimmunity. 200+ patients between the ages of 3 and 70 have been treated in 10 years of clinical research in Spain, China, and US. 70% of type 1 and type 2 diabetic patients demonstrated clinical efficacy. Many patients reduced insulin dosing and some have become insulin independent. This technology has been successfully tried in more than 10 autoimmune diseases including alopecia, lupus, fibrosis, and scleroderma. This therapy is ready to use and is approved to begin three FDA phase 2 clinical trials (type 1 diabetes, alopecia areata, COVID-19). Throne is looking to raise $5M to complete US FDA phase 2 through to commercialization. Throne is open to partnerships, joint ventures, investments, and license arrangements.

2nd Place – Praetego

Praetego is a pre-clinical stage pharmaceutical company with a mission to improve the health and longevity of diabetic patients. Praetego is developing novel small molecules (Amadorins) to alleviate serious diabetic complications, starting with peripheral neuropathy. Amadorins are first-in-class molecules able to inhibit a primary driver of diabetic microvascular disease and are derived from a clinically proven prototype.

3rd Place – Nano PharmaSolutions

A proprietary drug delivery nanotechnology that generates poorly soluble drugs as nanoparticles for better bioavailability. Our NanoTransformer(TM) technology can generate drug nanoparticles through phase transfer method without using any chemicals or solvent. We work with (1) preclinical stage drug developers for animal study formulations and (2) innovative generic companies for generic nanodrug development. We are at revenue stage and our revenue forecast is $150M in 2026 (our target exit time frame).

Congratulations to each of the winners, who have received free tickets to future RESI conferences to boost their fundraising efforts. Thank you to all finalists, judges, and attendees who make the IPC an exciting and powerful part of RESI! Interested in joining a future IPC? Applications are open for RESI Partnering Week September, featuring three separate RESI conferences! Select the logos below to learn more!

Apply for RESI IPC
Sept.13-15
Apply for RESI AI IPC
Sept.16-17
Apply for RESI Longevity IPC
Sept.16-17

Super early bird rates apply until July 9. Sign up now to save $100!

Panels at RESI Partnering Week September 13-17, 2021

17 Jun

By Rory McCann, Marketing Manager & Conference Producer, LSN

RESI Partnering Week returns September 13-17 and attendees can save $100 when they register by July 9! RESI Partnering Week is a five-day digital partnering experience connecting early-stage entrepreneurs in drugs, devices, diagnostics, and digital health with active investors who are a fit for their product and stage of development.

The RESI creators at Life Science Nation (LSN) understand that partnering is a multi-faceted process that takes time and commitment to yield fruitful relationships that turn into strategic partnerships. We offer several programs for attendees to take advantage of in order to optimize their experience, including our interactive panels that feature prominent life science and healthcare investors, as well as fundraising executives with their own tales from the road.

resi-sept-logo

  • Angels & Family Offices
  • Asia Cross Border
  • Big Pharma
  • Corporate VC
  • Medical Devices
  • Mental & Behavioral Health
  • Seed Funds
  • Tales from the Road

resi-ai-sept

  • Healthcare Communications
  • Reproductive Wellness
  • Healthcare Systems and Infrastructure
  • Accelerated Pharmaceutical Development
  • Diagnostic Wearables
  • Precision Medicine

resi-longevity-sept

  • Social Isolation & Loneliness
  • Health & Home Care
  • Medical Accountability & Adherence
  • Sensory Wellness

Contact us to learn more about RESI Partnering Week and how we can tailor the experience to meet your partnering needs.

For a demo, or to see how many investors in our a database are interested in your product, feel free to schedule a time that works best for you via LSN BD team’s Calendly link below.
International & MA (USA) West Coast (USA) East Coast (USA) & Canada Midwest (USA)
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!
Antoinette Lowre
Manager of Business Development
Schedule a call with me!

RESI Partnering Week Returns September 13-17

10 Jun

By Rory McCann, Marketing Manager & Conference Producer, LSN

RESI Partnering Week (RPW) returns September 13-17 for five days of match-based partnering, educational workshops, expert panels, innovative pitch sessions, and more!

RPW features a unique model made up of three days of Digital Redefining Early Stage Investments (RESI), followed by two days of targeted partnering and unique content designed specifically for age-tech and AI technology.

Get to know each event to see which are a fit for you! Super early bird rates are available until July 9, so register today to SAVE!

Redefining Early Stage Investments (RESI)

September 13-15, 2021

resi-sept-logoThe Redefining Early Stage Investments (RESI) conference series brings together startups with early-stage investors and strategic channel partners to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. RESI is cross-border and cross-domain, connecting start-ups with ten categories of global investors across the silos of drugs, devices, diagnostics, and digital health. RESI caters to both the earliest stage startups, those seeking grants, seed and angel capital, and the early-stage firms who seek seed, series A, and B funding.

RESI AI

September 16-17, 2021

resi-ai-septArtificial intelligence (AI) is rapidly reshaping the healthcare landscape and redefining what is possible in life science. RESI AI is a digital partnering conference that connects the investors and strategic partners and matches them to companies developing and commercializing AI technology in drugs, devices, diagnostics, and digital health to revolutionize healthcare. RESI AI features investors and entrepreneurs sharing their experiences in early-stage funding and what makes a successful partnership. This two-day digital conference provides the opportunity to meet and learn from experts, build relationships, and advance healthcare through the power of AI.

RESI Longevity

Co-Organized with Mary Furlong & Associates
September 16-17, 2021

resi-longevity-septThe aging boomer population contributed $8.3 trillion in economic activity to the 2018 US economy, and that number is projected to triple by 2050. The need for advancements in drugs, devices, diagnostics, and digital health for the treatment of age-related conditions is crucial. RESI Longevity is a new partnering conference focused on conditions related to aging, market challenges, and solutions via early-stage companies and their promising tech and products. RESI Longevity brings fundraising startups together with investors in age-tech innovation to make deals in order that today’s seniors live longer, healthier lives.

Learn more about what to expect at each event and how you can get involved!

1:1 Partnering

handshack_icon

The investors attending RESI represent a huge pool of capital, and Life Science Nation (LSN)’s unique partnering system enables fundraising companies find the investors and strategic partners that are a best fit for their technology and stage of development.

  • Review profiles of other participants.
  • Schedule one-on-one and/or group meetings.
  • Build your customized conference schedule, from panels to presentations to partnering meetings

Investor Panels & Workshops

panels_icon_new

Panels and workshops highlight panelists who can provide their perspective on current trends, as well as valuable advice to fundraising start-ups. From big corporations to angel groups, and from established VCs to family offices, the panelists participating at RESI reflect LSN’s global investor network. Panels will be live-streamed, giving audience members a chance to get their questions answered in real-time.

Innovator’s Pitch Challenge

ipc_icon_new

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.

Apply for RESI IPC
Sept.13-15
Apply for RESI AI IPC
Sept.16-17
Apply for RESI Longevity IPC
Sept.16-17

Virtual Exhibit Hall

exhibitor hall

Exhibitors and sponsors will be featured on a dedicated page with a virtual exhibitor booth, showcasing their services and the value they can provide. Participating tech hubs can highlight their programs and constituent companies.

Introducing RESI AI Panels

20 May

By Caitlin Dolegowski, Marketing Specialist, LSN

Caiti

Life Science Nation has released panel topics for its upcoming digital partnering conference: RESI AI, September 16-17. RESI AI panels host active investors who are joined by founders of portfolio companies to discuss funding, the early-stage landscape for AI companies in healthcare, and what makes a successful strategic partnership. Register by July 23 to save on super early bird rates.

There are many exciting advancements in this dynamic sector of life sciences, and we hope you’ll join us in highlighting the latest innovations, as well as take advantage of the powerful partnering system that has made RESI events a mainstay in early-stage fundraising.

If you’d like to be considered to join a RESI AI panel, please apply here.

The RESI AI panels will focus on the following topics:

Healthcare Communications

Bridging the Gaps between Patient and Provider

Communication between patients and providers is essential to health systems globally. AI-enabled technology addressing these needs and creating innovative solutions help patients better access and comprehend their options and care. Hear from early-stage founders connecting the healthcare system one relationship at a time.

Accelerated Pharmaceutical Development

Advancing and Optimizing Clinical Processes

AI is a necessary component of many aspects of the development of pharmaceuticals. However, the COVID-19 global pandemic has highlighted the need for rapid and reliable pharmaceutical advancement. Learn how researchers can utilize AI to optimize performance and save lives.

Reproductive Wellness

Highlighting Innovation and Broad Applications

Comprehensive reproductive care has a global impact on health and society. AI-assisted advancement in this field is critical to provide access to patients regardless of location, medical history, and socioeconomic status. Hear from leaders how their technology is creating equity in quality and excellence in care.

Diagnostic Wearables

Connecting Patients to Their Health

Wearable sensors are a fast-growing area of medical device and diagnostic technology. The function and accuracy of these devices are critical to patient care and communication. AI is a powerful tool equipping these to provide accurate results up to the moment and enabling users to make well-informed decisions on their health.

Healthcare Systems and Infrastructure

Creating Synergy for Efficient Patient Care

Optimized healthcare systems and digital infrastructure are paramount to the patient experience. From electronic health records to portal access and communications, AI-enabled medical centers are better equipped to help patients in the digital age. When it comes to healthcare, small synergistic changes create a big impact on the patient experience and contribute to better systems globally.

Precision Medicine

Fitting the AI Piece of the Puzzle

The AI impact on precision medicine is essential in targeting and treating genetic disorders, rare diseases, oncology, and more. It’s important that entrepreneurs learn how to navigate pitfalls such as market saturation, regulatory risk and guidelines, as well as how to better define patient populations, challenges and tackle manufacturing and commercialization.

Introducing RESI AI Panels

18 May

By Elizabeth Murphy, Manager of Business Development, LSN

It is with great pleasure that we announce the upcoming panel discussions for the RESI AI digital partnering conference, September 16-17. Register by July 23 to save on super early bird rates and save an additional $100 with code: MANDATE100.

Apply here for the chance to join one of the following panel discussions:

Healthcare Communications

Bridging the Gaps between Patient and Provider

Communication between patients and providers is essential to health systems globally. AI-enabled technology addressing these needs and creating innovative solutions help patients better access and comprehend their options and care. Hear from early-stage founders connecting the healthcare system one relationship at a time.

Accelerated Pharmaceutical Development

Advancing and Optimizing Clinical Processes

AI is a necessary component of many aspects of the development of pharmaceuticals. However, the COVID-19 global pandemic has highlighted the need for rapid and reliable pharmaceutical advancement. Learn how researchers can utilize AI to optimize performance and save lives.

Reproductive Wellness

Highlighting Innovation and Broad Applications

Comprehensive reproductive care has a global impact on health and society. AI-assisted advancement in this field is critical to provide access to patients regardless of location, medical history, and socioeconomic status. Hear from leaders how their technology is creating equity in quality and excellence in care.

Diagnostic Wearables

Connecting Patients to Their Health

Wearable sensors are a fast-growing area of medical device and diagnostic technology. The function and accuracy of these devices are critical to patient care and communication. AI is a powerful tool equipping these to provide accurate results up to the moment and enabling users to make well-informed decisions on their health.

Healthcare Systems and Infrastructure

Creating Synergy for Efficient Patient Care

Optimized healthcare systems and digital infrastructure are paramount to the patient experience. From electronic health records to portal access and communications, AI-enabled medical centers are better equipped to help patients in the digital age. When it comes to healthcare, small synergistic changes create a big impact on the patient experience and contribute to better systems globally.

Precision Medicine

Fitting the AI Piece of the Puzzle

The AI impact on precision medicine is essential in targeting and treating genetic disorders, rare diseases, oncology, and more. It’s important that entrepreneurs learn how to navigate pitfalls such as market saturation, regulatory risk and guidelines, as well as how to better define patient populations, and tackle manufacturing and commercialization challenges.

Hot AI Mandate: DeepTech-focused VC Invests In AI/Data-driven Technologies in Healthcare

11 May

A venture capital firm with offices in Palo Alto and California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has over $2B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm is also interested in synthetic biology. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of concept and traction, and prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot AI Mandate: Canada-based Family Office Looking for Big-data or AI-related Opportunities in Healthcare

11 May

A single family office founded in 2009 and based in Toronto is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space and may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

%d bloggers like this: